225 related articles for article (PubMed ID: 14651778)
1. Deregulated expression of interferon regulatory factor-1 in oncogene-transformed mouse fibroblasts.
Contente S; Attard FA; Yeh TJ; Buchhagen DL; Friedman RM
J Interferon Cytokine Res; 2003 Nov; 23(11):639-47. PubMed ID: 14651778
[TBL] [Abstract][Full Text] [Related]
2. Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression.
Tan RS; Taniguchi T; Harada H
Cancer Res; 1996 May; 56(10):2417-21. PubMed ID: 8625321
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.
Contente S; Kenyon K; Sriraman P; Subramanyan S; Friedman RM
Mol Cell Biochem; 1999 Apr; 194(1-2):79-91. PubMed ID: 10391127
[TBL] [Abstract][Full Text] [Related]
4. IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo.
Kröger A; Dallügge A; Kirchhoff S; Hauser H
Oncogene; 2003 Feb; 22(7):1045-56. PubMed ID: 12592391
[TBL] [Abstract][Full Text] [Related]
5. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis.
Kirchhoff S; Hauser H
Oncogene; 1999 Jun; 18(25):3725-36. PubMed ID: 10391680
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of deregulation of IFN regulatory factor-1 in ras-transformed fibroblasts.
Attard FA; Contente S; Yeh TJ; Buchhagen DL; Friedman RM
J Interferon Cytokine Res; 2005 Jul; 25(7):418-23. PubMed ID: 16022587
[TBL] [Abstract][Full Text] [Related]
7. Transformation of revertant murine cells by 5-azacytidine results in rapid inhibition of lysyl oxidase expression.
Yeh TJ; Contente S; Friedman RM
Acta Microbiol Immunol Hung; 2005; 52(3-4):433-42. PubMed ID: 16400881
[TBL] [Abstract][Full Text] [Related]
8. Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.
Nguyen H; Mustafa A; Hiscott J; Lin R
Oncogene; 1995 Aug; 11(3):537-44. PubMed ID: 7630638
[TBL] [Abstract][Full Text] [Related]
9. Interferon-gamma regulation of the human mimecan promoter.
Tasheva ES; Conrad GW
Mol Vis; 2003 Jun; 9():277-87. PubMed ID: 12835654
[TBL] [Abstract][Full Text] [Related]
10. Comparative functional study of the lysyl oxidase promoter in fibroblasts, Ras-transformed fibroblasts, myofibroblasts and smooth muscle cells.
Reynaud C; Gleyzal C; Jourdan-Le Saux C; Sommer P
Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1237-47. PubMed ID: 10643973
[TBL] [Abstract][Full Text] [Related]
11. SCH 51344 inhibits ras transformation by a novel mechanism.
Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A
Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors.
Lee AH; Hong JH; Seo YS
Biochem J; 2000 Aug; 350 Pt 1(Pt 1):131-8. PubMed ID: 10926836
[TBL] [Abstract][Full Text] [Related]
13. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor confers resistance to the antiproliferative effect of interferon-alpha.
Flowers CC; Flowers SP; Nabel GJ
Mol Med; 1998 Jun; 4(6):402-12. PubMed ID: 10780883
[TBL] [Abstract][Full Text] [Related]
14. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1.
Tanaka N; Ishihara M; Kitagawa M; Harada H; Kimura T; Matsuyama T; Lamphier MS; Aizawa S; Mak TW; Taniguchi T
Cell; 1994 Jun; 77(6):829-39. PubMed ID: 8004672
[TBL] [Abstract][Full Text] [Related]
15. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
16. Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: constitutive interleukin-1 alpha transcription and manifestation of biological activity.
Douvdevani A; Huleihel M; Segal S; Apte RN
Eur Cytokine Netw; 1991; 2(4):257-64. PubMed ID: 1756231
[TBL] [Abstract][Full Text] [Related]
17. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.
Harada H; Kitagawa M; Tanaka N; Yamamoto H; Harada K; Ishihara M; Taniguchi T
Science; 1993 Feb; 259(5097):971-4. PubMed ID: 8438157
[TBL] [Abstract][Full Text] [Related]
18. Differential growth factor expression in transformed mouse NIH-3T3 cells.
Ciardiello F; Valverius EM; Colucci-D'Amato GL; Kim N; Bassin RH; Salomon DS
J Cell Biochem; 1990 Jan; 42(1):45-57. PubMed ID: 1967612
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter.
Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA
Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800
[TBL] [Abstract][Full Text] [Related]
20. Interferon regulatory factor-1 (IRF-1) is a mediator for interferon-gamma induced attenuation of telomerase activity and human telomerase reverse transcriptase (hTERT) expression.
Lee SH; Kim JW; Lee HW; Cho YS; Oh SH; Kim YJ; Jung CH; Zhang W; Lee JH
Oncogene; 2003 Jan; 22(3):381-91. PubMed ID: 12545159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
